Incidence of superficial venous thrombosis in primary care and risk of subsequent venous thromboembolic sequelae: a retrospective cohort study performed with routine healthcare data from the Netherlands
- PMID: 29678975
- PMCID: PMC5914716
- DOI: 10.1136/bmjopen-2017-019967
Incidence of superficial venous thrombosis in primary care and risk of subsequent venous thromboembolic sequelae: a retrospective cohort study performed with routine healthcare data from the Netherlands
Abstract
Objectives: Recent studies in referred populations of patients with superficial venous thrombosis (SVT) report risks of venous thromboembolic (VTE) sequelae (deep vein thrombosis or pulmonary embolism) as high as 25%. Likely, these estimates are lower in non-referred patients, but large-scale population-based studies are lacking. We aimed to estimate the incidence rate of SVT in primary care and quantify its risk of VTE sequelae.
Design: A retrospective cohort study, using International Classification of Primary Care coding (K94.02) combined with free text searching (synonyms for SVT) to capture all SVT events. All patients were followed up for 3 months using manual free text searching.
Setting: Primary care.
Participants: All patients enlisted with general practitioners within the Utrecht General Practitioner Network between 2010 and 2016 (1 534 845 person-years follow-up).
Main outcome measures: The incidence rate of SVT was expressed as the number of SVT events per 1000 person-years of follow-up and the 3-month cumulative incidence of VTE events was calculated. Logistic regression analysis was used to compare patients with SVT with and without VTE sequelae.
Results: A total of 2008 SVT cases were identified, that is, an SVT incidence rate of 1.31 (95% CI 1.25 to 1.37) per 1000 person-years follow-up, with higher rates notably with increasing age. VTE sequelae occurred in 83 patients; 51 at the time of SVT diagnosis and 32 patients during follow-up (total cumulative incidence of 4.1%; 95% CI 3.3% to 5.1%), and were more frequent in those with an active malignancy (OR 2.19; 95% 0.97 to 4.95) and less frequent in those with varicose veins at baseline (OR 0.57, 95% CI 0.34 to 0.94).
Conclusion: We found an incidence rate of SVT in primary care of 1.31 per 1000 person-years. The risks of VTE sequelae was relatively low at 4.1%, with the highest risk in patients with cancer and in those who experience an SVT in the absence of varicose veins.
Keywords: anticoagulation; primary care; thromboembolism.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Long-term risk of venous thromboembolism recurrence after isolated superficial vein thrombosis.J Thromb Haemost. 2017 Jun;15(6):1123-1131. doi: 10.1111/jth.13679. Epub 2017 May 5. J Thromb Haemost. 2017. PMID: 28317330
-
Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.Eur J Vasc Endovasc Surg. 2023 Nov;66(5):697-704. doi: 10.1016/j.ejvs.2023.08.031. Epub 2023 Aug 12. Eur J Vasc Endovasc Surg. 2023. PMID: 37573936
-
Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study.Ann Intern Med. 2010 Feb 16;152(4):218-24. doi: 10.7326/0003-4819-152-4-201002160-00006. Ann Intern Med. 2010. PMID: 20157136
-
A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019.J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1099-1111.e6. doi: 10.1016/j.jvsv.2021.01.012. Epub 2021 Jan 30. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33529719 Free PMC article.
-
Medical management of acute superficial vein thrombosis of the saphenous vein.J Vasc Surg Venous Lymphat Disord. 2018 Jan;6(1):109-117. doi: 10.1016/j.jvsv.2017.08.016. Epub 2017 Oct 31. J Vasc Surg Venous Lymphat Disord. 2018. PMID: 29097174 Review.
Cited by
-
The Diagnostic Utility of Natural Killer Cell Subsets in Deep Vein Thrombosis.Vasc Health Risk Manag. 2023 Nov 23;19:779-787. doi: 10.2147/VHRM.S430466. eCollection 2023. Vasc Health Risk Manag. 2023. PMID: 38025520 Free PMC article.
-
Treatment of Superficial Vein Thrombosis: Recent Advances, Unmet Needs and Future Directions.Healthcare (Basel). 2024 Jul 31;12(15):1517. doi: 10.3390/healthcare12151517. Healthcare (Basel). 2024. PMID: 39120220 Free PMC article. Review.
-
Predictive factors of clot propagation in patients with superficial venous thrombosis towards deep venous thrombosis and pulmonary embolism: a systematic review and meta-analysis.BMJ Open. 2024 Apr 16;14(4):e074818. doi: 10.1136/bmjopen-2023-074818. BMJ Open. 2024. PMID: 38626964 Free PMC article.
-
Superficial Vein Thrombosis and Severe Varicose Veins Complicating Venous Thromboembolism.J Cardiovasc Imaging. 2019 Apr;27(2):154-155. doi: 10.4250/jcvi.2019.27.e14. J Cardiovasc Imaging. 2019. PMID: 30993952 Free PMC article. No abstract available.
-
Management of Superficial Vein Thrombosis in Patients with Varicose Veins: A Survey among Members of National Surgical Society from Republic of Moldova.Vasc Specialist Int. 2020 Jun 30;36(2):105-111. doi: 10.5758/vsi.200021. Vasc Specialist Int. 2020. PMID: 32611843 Free PMC article.
References
-
- Decousus H, Quéré I Presles E, et al. . Superficial venous thrombosis and venous thromboembolism. Ann Intern Med 2010;152:218. - PubMed
-
- Beyer-Westendorf J, Schellong SM, Gerlach H, et al. . Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol 2017;4:e105–e113. 10.1016/S2352-3026(17)30014-5 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical